Market capitalization | $904.56m |
Enterprise Value | $24.90m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.05 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-158.35m |
Free Cash Flow (TTM) Free Cash Flow | $-117.99m |
Cash position | $883.52m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
13 Analysts have issued a Structure Therapeutics forecast:
13 Analysts have issued a Structure Therapeutics forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -3.03 -3.03 |
219%
219%
|
|
EBITDA | -155 -155 |
53%
53%
|
EBIT (Operating Income) EBIT | -158 -158 |
54%
54%
|
Net Profit | -123 -123 |
37%
37%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company engaged in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in San Francisco, CA.
Head office | Cayman Islands |
CEO | Raymond Stevens |
Employees | 163 |
Founded | 2019 |
Website | www.structuretx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.